Baculovirus-based vaccines
AssigneesKonkuk University Industrial Cooperation Corp., KR Biotech Co., Ltd.
InventorsYoung-Bong Kim, Hee Jung Lee, Nuri Park, Yu-Kyoung Oh
Life of this patent
Estimating the term…
Abstract
The present invention relates to a recombinant baculovirus comprising: (a) a nucleotide sequence encoding a foreign virus envelope protein; (b) a first promoter operatively linked to the envelope-encoding nucleotide sequence; (c) a nucleotide sequence encoding an antigen protein; and (d) a second promoter operatively linked to the antigen-encoding nucleotide sequence; and a vaccine composition using the same. The recombinant baculovirus of the present invention has an excellent efficacy on both humoral and cellular immune responses against a specific antigen (e.g., HPV L1), enabling to function as a more efficient DNA vaccine.
Claims10
A method for inducing an immune response against a specific antigen in a mammalian subject in need thereof, comprising:
- (a) transfecting into an insect cell a recombinant bacmid comprising (i) a nucleotide sequence encoding an envelope protein of an endogenous retrovirus;
- (ii) a first promoter that is operable in the insect cell and is operatively linked to (i);
- (iii) a nucleotide sequence encoding a second antigen protein not from any baculovirus and endogenous retrovirus;
- and (iv) a second promoter that is from a mammalian genome or virus, which is different the first promoter and is operatively linked to (iii);
- (b) obtaining a recombinant baculovirus vector produced from the insect cell, wherein the recombinant baculovirus vector is an endogenous retrovirus envelope-coated Baculovirus vector to express the second antigen;
- and (c) administering a pharmaceutically effective amount of the recombinant baculovirus of (b) to the mammalian subject.
Dependencies are inferred from the claim text.